Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TYMP | P19971 | 12/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820911 | 0.93 | KDM4E (0.64) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL3820908 | 0.93 | KDM4E (0.64) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL8442735 | 0.93 | KDM4E (0.56) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL26190487 | 0.92 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL21828783 | 0.92 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL3819153 | 0.92 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL14063336 | 0.92 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL17911710 | 0.92 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL3819157 | 0.92 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL14062506 | 0.92 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1253154-B1 | Method for purifying 5'-protected 2'-deoxypurine nucleosides | MITSUI CHEMICALS INC (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-7074917-B2 | Method for purifying 5′ -protected 2′ -deoxypurine nucleosides | MITSUI CHEMICALS, INC. (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20060009635-A1 | Method for purifying 5' -protected 2' -deoxypurine nucleosides | MITSUI CHEMICALS, INC. (JP) | 2006-01-12 | — | — | US | disclosed |
| US-6958391-B2 | Method for purifying 5′-protected 2′-deoxypurine nucleosides | MITSUI CHEMICALS, INC. (JP) | 2005-10-25 | — | — | US | disclosed |
| US-20030009028-A1 | Method for purifying 5' -protected 2' -deoxypurine nucleosides | MITSUI CHEMICALS, INC. (JP) | 2003-01-09 | — | — | US | disclosed |
| EP-1253154-A1 | Method for purifying 5'-protected 2'-deoxypurine nucleosides | Mitsui Chemicals, Inc. (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009028-A1 | Method for purifying 5' -protected 2' -deoxypurine nucleosides | PNP, UMPS, NT5C3B | KDM4E 2214/4885TYMP 8/4885TAS1R3 4793/4885 |
| US-20060009635-A1 | Method for purifying 5' -protected 2' -deoxypurine nucleosides | PNP, UMPS, NUDT1 | KDM4E 2375/4885TYMP 7/4885TAS1R3 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.